US20030083236A1 - Myelopeptides and their therapeutic use - Google Patents

Myelopeptides and their therapeutic use Download PDF

Info

Publication number
US20030083236A1
US20030083236A1 US10/277,622 US27762202A US2003083236A1 US 20030083236 A1 US20030083236 A1 US 20030083236A1 US 27762202 A US27762202 A US 27762202A US 2003083236 A1 US2003083236 A1 US 2003083236A1
Authority
US
United States
Prior art keywords
pro
peptide according
cells
amino acids
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/277,622
Inventor
Rem Petrov
Augusta Mikhailova
Larissa Fonina
Sergei Guriyanov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harness Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/277,622 priority Critical patent/US20030083236A1/en
Publication of US20030083236A1 publication Critical patent/US20030083236A1/en
Assigned to ZERONORTH, INC. reassignment ZERONORTH, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: CYBRIC Inc.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to myelopeptides and their therapeutic use.
  • MPs myelopeptides
  • WO-A-9618652 discloses hexapeptides, having antitumour activity, of the formula Y 1 -Y 2 -Y 3 -Tyr-Pro-Trp.
  • An example is MP-2.
  • novel peptides have therapeutic utility. For example, they may be used where immunostimulating or antiviral activity is required. In particular, they may induce production of interferon(s), inhibit replication of viruses, including HIV, thereby providing a protective effect in mammals, and increase immune resistance towards bacterial infection.
  • novel peptides have been obtained from natural sources, using conventional procedures. They or other peptides of the invention may also be prepared by synthetic procedures that are known to those of ordinary skill in the art, e.g. the well known solid phase method.
  • novel peptides are defined in the claims. They may be tetra-, penta-, hexa-, hepta-, octa-, nona- or deca-peptides. Specific examples are LVCYPQ (herein MP-3), FRPRIMTP (MP-4), VVYPD (MP-5) and VDPP (MP-6), and data for these peptides are presented below. As will be evident from the results, these peptides do not have uniform characteristics. It will however also be evident that suitable tests can be made, to determine which is most suited for any particular application.
  • Peptides of the invention may be made up into pharmaceutical formulations of any suitable type, using known carriers or diluents, e.g. as solutions or dispersions to be administered, with or without an adjuvant.
  • the amount of the peptide that is administered will be chosen with regard to factors such as the route of administration, the severity of the conditions, the age and health of the patient etc. The skilled physician will be able to select appropriate amounts, e.g. based on the effective dosages reported in the following results.
  • Phagocytosis of opsonized sheep red blood cells (SRBC) by murine peritoneal macrophages was measured in the NBT-test (reduction of nitro blue tetrazolium by superoxide anions released by macrophages during an oxidative burst).
  • Peritoneal cells were obtained from mice (CBAxC57B1)F1 plated per well in 96-well flat-bottom plates (1 ⁇ 10 6 cells/well) in 199 medium. After 2 h incubation at 37° C. in an atmosphere of 5% CO 2 in air, non-adherent cells were removed by vigorous washing with warmed Hank's balanced salt solution (BSS).
  • BSS Hank's balanced salt solution
  • MP-3 stimulates macrophage phagocytosis in a dose-dependent manner.
  • the dose curve has a bimodal character. Maximal stimulation, up to 250%, occurs at doses of 10 ⁇ 8 -10 ⁇ 7 g/ml. There is one more peak of macrophage stimulation (at doses of 10 ⁇ 16 -19 ⁇ 17 g/ml). This effect is less pronounced but statistically significant (p ⁇ 0.05).
  • MP-3 was used to inoculate (CBAxC57BL)F1 mice l/p at doses of 0.5 ⁇ 10 ⁇ 4 g/mouse and 1 ⁇ 10 ⁇ 6 g/mouse. 24 hours later, these mice were infected with various doses of Salmonella typhimurium 415 (10 2 , 10 3 , 10 4 or 10 5 bacterial cells/mouse). The mice of a control group were inoculated with saline solution. Each group contained 10 mice. The life span of each mouse was followed over 21 days.
  • Acute bacterial infection was induced in laboratory mice of (CBAxC57B1)F1 origin using an intraperitoneal injection of 100 LD 50 Salmonella thyphi which actually was 1,000 microbe bodies. The infection caused a rapidly progressing sepsis and death of 100% animals within 3 days of such challenge.
  • Placebo control animals were injected intraperitoneally or subcutaneously using 0.2 ml of 0.85% NaCl saline 24 h before challenge. Then these animals were subjected to the same procedure of infection using 100 LD 50 of S. thyphi. All the control animals died within 3 days, as if they were just challenged without any pre-treatment.
  • the pre-treatment of mice using intraperitoneal or subcutaneous injection of MP-3, MP-4, MP-5 or MP-6, 24 h before the lethal challenge by 100 LD 50 S. thyphi saved most of the animals. The MP's protection was dose-dependent.
  • the MPs used at 1-10 ⁇ g doses per mouse, defended 90-100% of animals from subsequent challenge by the lethal dose of Salmonella. Both routes of injection, intraperitoneal and subcutaneous, were shown to be quite effective for pre-treatment using the MPs.
  • HL-60 cell line was obtained from bone marrow cells of patients with acute myeloid leukaemia. These cells are myelomonoblasts which are intensively proliferating. They can differentiate to granuloid or monocyte pathway only in the presence of appropriate stimulants.
  • the human myeloid HL-60 line was maintained in standard medium: RPMI-1640 medium supplemented with 15% (v/v) heat-inactivated fetal calf serum, 20 mM HEPES, 2 mM L-glutamine and 50 ⁇ g/ml gentamycin.
  • the initial cell concentration was 2 ⁇ 10 5 cells/ml.
  • the cells were cultivated at 37° C. in an atmosphere of 5% CO 2 in air.
  • MP-4 was added to the culture at concentrations from 1 ⁇ 10 ⁇ 2 to 1 ⁇ 10 2 g/ml. After 3 days of cultivation, the cells were washed and reincubated in fresh cultural medium.
  • each culture was labelled with 3 H-thymidine and 14 C-glycine, 4 hours before termination of culture.
  • the cells were harvested on the 6th day of cultivation and their DNA ( 3 H) and protein ( 14 C) radioactivity was measured. The mean counts per min (cpm) in triplicate culture were analyzed.
  • Each of the experimental groups of animals was represented by 25 mice receiving the same dose of a preparation. 4, 24, 48, 72 or 96 h after injection, 5 mice of each experimental group were sacrificed, their serum samples pooled and stored frozen at ⁇ 60° C. until the interferon activity of the pooled serum measured. The latter measurement was performed by testing serum anti-viral activity in the in vitro cell cultures infected by encephalomyocarditis virus (EMV).
  • EMV encephalomyocarditis virus
  • L929 fibroblastoid cell line were grown in alpha-MEM culture medium supplemented with 10% FBS. Cultures of 200,000 cells suspended in 0.1 ml of the culture medium were placed into wells of 96-well microplate and incubated in an atmosphere of 5% CO 2 at 37° C. The L929 cell cultures were infected using 100 TCIC 50 dose of the established laboratory strain of EMV. Cytopathological damage in cell morphology was recorded 24 h from infection.
  • Factor 2 serial dilutions of each serum sample were made using alpha-MEM culture medium containing FBS. 0.1 ml of the designated dilution of serum sample was added into each microwell containing L929 cell culture at the point of its infection with EMV.
  • mice In the control groups of mice, the strongest of known interferon inducers were used. Namely, Newcastle disease virus (NDS) and Ridostin were used as a positive control to be compared with MPs by their serum interferon-increasing activity.
  • NDS Newcastle disease virus
  • Ridostin Ridostin
  • MP-3 and MP-6 weakly induced late interferon in the mouse serum. Levels of 20 and 40 units/ml, respectively, were achieved 48 h after a single injection of 1-10 ⁇ g MP-3 and 0.1-1 ⁇ g MP-6.
  • the MPs Being capable of inducing serum interferon increase in vivo, the MPs most probably induce synthesis of interferon in the appropriate cell culture in vitro. If so, this can be monitored according to these compounds' anti-viral action in cell culture in vitro, when infected by actively replicating virus.
  • L929 mouse cells acutely infected by encephalomyocarditis virus was used as a model to define active concentrations of MP-3, MP-4, MP-5 and MP-6 as related to their capability to induce interferon synthesis in mammalian cells and hence block viral infection in these cells.
  • the L929 mouse fibroblastoid cell line was maintained in vitro as described above.
  • MP-3, MP-4, MP-5 and MP-6 were added into triplicate cultures using the following final concentrations: 500, 250, 125, 63, 31, 16, 8, 4, 2, 1, 0.5, 0.25 ⁇ g per 1 ml of culture.
  • Ridostin was used as a control interferon-inducer.
  • the L929 cell cultures were infected by 100 TCID 50 of EMV. During the next 24 h the viral infection caused dramatic damages in L929 cells. When the cultures were pre-incubated in the presence of MP-3, it did not prevent the cell layers from extensive damage caused by subsequent virus infection using 100 TCID 50 of EMV. MP-5, by contrast, when added in a final concentration of 16 ⁇ g/ml or more, completely abrogated destructive influence of the virus on L929 cells. So did MP-6, when added at a concentration of 4 ⁇ g/ml or more. The anti-viral effect of MP-5 and MP-6 was quite comparable to that of Ridostin added at 0.5 ⁇ g/ml or more. MP-4 also defended the L929 cells from the virus-induced damage, after 48 h exposure of the cells in the presence of 32 ⁇ g/ml (or higher concentration) of the preparation before their challenge by the virus.
  • the interferon-inducing capacities of the MPs was examined in both L-41 human cell line and healthy donor peripheral blood cell (PBC) cultures.
  • L-41 cells were maintained in medium 199 supplemented by 10% FBS and antibiotics.
  • 200,000 cells per 1 ml of culture medium were placed in the wells of 24-well plastic culture plates and grown at 37° C. in the atmosphere of 5% CO 2 /
  • the control and experimental interferon-inducers were introduced in the cultures in the centration desired. 24 h after interferon induction, the culture supernatants were harvested and then examined for interferon content.
  • the healthy donor PBC were incubated in the wells of 96-well culture plates and the culture supernatants were harvested 24 h after the test preparation was added to the culture.
  • the HIV-infected MT4 cells were incubated in RPMI-1640 culture medium supplemented with 10% FBS and 2 mM L-glutamine.
  • the MT4 cells (0.5 million cells per 1 ml of culture medium) were placed in wells of a 24-well plastic culture plates and kept for 7 days of 37° C. in an atmosphere of 4.5% CO 2 .
  • Each of the MPs examined was added into respective wells of the culture plates, to final concentrations of 0.1, 0.5, 1, 5, 10, 50 and 100 ⁇ g per 1 ml of culture were used.
  • Azidothymidine (Sigma Chemical Co.) at its final concentration of 0.1 ⁇ g/ml, was used as a positive anti-viral control during each of the experiments.

Abstract

The present invention pertains to peptides comprising 4 to 10 amino acids including X1-Pro, Pro-X2 or X1-Pro-X2, wherein X1 and X2 are independently selected from Lys, Arg, His, Asp, Glu, Asn and Gln, and the other amino acids are independently selected from Gly, Ala, Val, Leu, Ile, Nle, Nva, Pro, Phe, Tyr, Trp, Cys, Met, Ser and Thr. Such peptides, including LVCYPQ, FRPRIMTP, VVYPD and VDPP, are obtainable from porcine bone marrow cell culture, and have immunostimulating and anti-viral properties.

Description

    FIELD OF THE INVENTION
  • This invention relates to myelopeptides and their therapeutic use. [0001]
    • BACKGROUND OF THE INVENTION
  • As reported by Mikhailova et al, Immun. Lett. 47:199-203 (1995), and in WO-A-9618652, the bone marrow cells of various animals and humans produce a group of bioregulatory peptides named myelopeptides (MPs). MPs have a wide spectrum of functional activities: immunoregulatory, differentiating and opiate-like. They evoke 2-3-fold stimulation of antibody production to various antigens and correct some immune disorders. MPs influence the differentiation of bone marrow and peripheral blood cells derived from healthy and leukaemic donors. They induce terminal differentiation in the leukaemic human HL-60 cell line, and show an effect on pain sensitivity. [0002]
  • More specifically, Mikhailova et al report two specific hexapeptides having immunoregulatory properties, i.e. FLGFPT (MP-1) and LVVYPW (MP-2). WO-A-9618652 discloses hexapeptides, having antitumour activity, of the formula Y[0003] 1-Y2-Y3-Tyr-Pro-Trp. An example is MP-2.
    • SUMMARY OF THE INVENTION
  • Further peptides have been isolated from the supernatant of porcine bone marrow cell culture by means of successive solid phase extraction and HPLC. These novel peptides are of the type comprising 4 to 10 amino-acids including Pro-X and/or X-Pro, X being a hydrophilic amino-acid, and which typically otherwise comprise hydrophobic amino-acids. [0004]
  • The novel peptides have therapeutic utility. For example, they may be used where immunostimulating or antiviral activity is required. In particular, they may induce production of interferon(s), inhibit replication of viruses, including HIV, thereby providing a protective effect in mammals, and increase immune resistance towards bacterial infection. [0005]
    • DESCRIPTION OF THE INVENTION
  • As indicated above, certain novel peptides have been obtained from natural sources, using conventional procedures. They or other peptides of the invention may also be prepared by synthetic procedures that are known to those of ordinary skill in the art, e.g. the well known solid phase method. [0006]
  • Various preferred characteristics of the novel peptides are defined in the claims. They may be tetra-, penta-, hexa-, hepta-, octa-, nona- or deca-peptides. Specific examples are LVCYPQ (herein MP-3), FRPRIMTP (MP-4), VVYPD (MP-5) and VDPP (MP-6), and data for these peptides are presented below. As will be evident from the results, these peptides do not have uniform characteristics. It will however also be evident that suitable tests can be made, to determine which is most suited for any particular application. [0007]
  • Peptides of the invention may be made up into pharmaceutical formulations of any suitable type, using known carriers or diluents, e.g. as solutions or dispersions to be administered, with or without an adjuvant. The amount of the peptide that is administered will be chosen with regard to factors such as the route of administration, the severity of the conditions, the age and health of the patient etc. The skilled physician will be able to select appropriate amounts, e.g. based on the effective dosages reported in the following results. [0008]
  • MP-3 Stimulates Macrophage Phagocytosis [0009]
  • Phagocytosis of opsonized sheep red blood cells (SRBC) by murine peritoneal macrophages was measured in the NBT-test (reduction of nitro blue tetrazolium by superoxide anions released by macrophages during an oxidative burst). Peritoneal cells were obtained from mice (CBAxC57B1)F1 plated per well in 96-well flat-bottom plates (1×10[0010] 6 cells/well) in 199 medium. After 2 h incubation at 37° C. in an atmosphere of 5% CO2 in air, non-adherent cells were removed by vigorous washing with warmed Hank's balanced salt solution (BSS). 100 μl of NBT solution (1 mg/ml), 50 μl 1% suspension of opsonized SRBC and MP-3, MP-1 or MP-2 at concentrations from 10−6 to 10−18 g/ml were added to the wells. Control wells had no MPs. After 1 hour incubation at 37° C., the cells were washed with BSS and fixed with 10% formalin solution. 10 min later, the cells were washed with distilled water and dried. The insoluble blue formazan was solubilized by adding first 60 μl/well 2M KOH and then 70 μl/well dimethyl sulphoxide (DMSO). The contents of the wells were then mixed to complete solubilisation. The final solution had an intense turquoise-blue colour. The OD620 was read on an ELISA reader Multiskan MCC/340. The level of phagocytosis in each well treated with MPs was compared to that in a control well (100%).
  • By contrast to MP-1 and MP-2, MP-3 stimulates macrophage phagocytosis in a dose-dependent manner. The dose curve has a bimodal character. Maximal stimulation, up to 250%, occurs at doses of 10[0011] −8-10−7 g/ml. There is one more peak of macrophage stimulation (at doses of 10−16-19−17 g/ml). This effect is less pronounced but statistically significant (p<0.05).
  • It may be concluded that the stimulation of macrophage phagocytosis by MP-3 results in its protective effect in infected animals. [0012]
  • MP-3 Increases the Survival of Mice Infected with [0013] Salmonella typhimurium
  • MP-3 was used to inoculate (CBAxC57BL)F1 mice l/p at doses of 0.5×10[0014] −4 g/mouse and 1×10−6 g/mouse. 24 hours later, these mice were infected with various doses of Salmonella typhimurium 415 (102, 103, 104 or 105 bacterial cells/mouse). The mice of a control group were inoculated with saline solution. Each group contained 10 mice. The life span of each mouse was followed over 21 days.
  • A pronounced protective effect of MP-3 was obtained at both doses used. At the level of 100% death in controls (10[0015] −5 and 10−4 bacterial cells/mouse), survival in the groups treated with MP-3 was 70-90%. At the level of 50% death in a control (102 bacterial cells/mouse), all mice treated with MP-3 stayed alive. This suggests that MP-3 protects the animals from bacterial infection due to its ability to stimulate macrophage phagocytosis.
  • MPs Induce Resistance to Lethal Bacterial Infection [0016]
  • Acute bacterial infection was induced in laboratory mice of (CBAxC57B1)F1 origin using an intraperitoneal injection of 100 LD[0017] 50 Salmonella thyphi which actually was 1,000 microbe bodies. The infection caused a rapidly progressing sepsis and death of 100% animals within 3 days of such challenge.
  • Placebo control animals were injected intraperitoneally or subcutaneously using 0.2 ml of 0.85% NaCl saline 24 h before challenge. Then these animals were subjected to the same procedure of infection using 100 LD[0018] 50 of S. thyphi. All the control animals died within 3 days, as if they were just challenged without any pre-treatment. By contrast, the pre-treatment of mice using intraperitoneal or subcutaneous injection of MP-3, MP-4, MP-5 or MP-6, 24 h before the lethal challenge by 100 LD50 S. thyphi, saved most of the animals. The MP's protection was dose-dependent.
  • The MPs, used at 1-10 μg doses per mouse, defended 90-100% of animals from subsequent challenge by the lethal dose of Salmonella. Both routes of injection, intraperitoneal and subcutaneous, were shown to be quite effective for pre-treatment using the MPs. [0019]
  • MP-4 Induces Terminal Differentiation in Leukaemia Cells [0020]
  • HL-60 cell line was obtained from bone marrow cells of patients with acute myeloid leukaemia. These cells are myelomonoblasts which are intensively proliferating. They can differentiate to granuloid or monocyte pathway only in the presence of appropriate stimulants. [0021]
  • The human myeloid HL-60 line was maintained in standard medium: RPMI-1640 medium supplemented with 15% (v/v) heat-inactivated fetal calf serum, 20 mM HEPES, 2 mM L-glutamine and 50 μg/ml gentamycin. The initial cell concentration was 2×10[0022] 5 cells/ml. The cells were cultivated at 37° C. in an atmosphere of 5% CO2 in air. MP-4 was added to the culture at concentrations from 1×10−2 to 1×102 g/ml. After 3 days of cultivation, the cells were washed and reincubated in fresh cultural medium. 3 days later, each culture was labelled with 3H-thymidine and 14C-glycine, 4 hours before termination of culture. The cells were harvested on the 6th day of cultivation and their DNA (3H) and protein (14C) radioactivity was measured. The mean counts per min (cpm) in triplicate culture were analyzed.
  • It is known that a decrease in chromosomal DNA synthesis and an increase of total protein synthesis without histones are characteristic of the differentiation process. From changes of the ratio of [0023] 3H/14C incorporation, it could be seen that MP-4 induces the differentiation process in HL-60 cells. The MP-4 effect on blastoid cells HL-60 is dose-dependent. The optimal dose is 0.1-5.0 μg/ml.
  • Morphological analysis of HL-60 cells treated with MP-4 confirmed these results. There were about 60% mature forms (monocytes-macrophages) among blastoid cells. The differentiating effect of MP-4 was compared with that of the known differentiating factors phorbol myristate acetate and maturation inducer (T-lymphocyte differentiating factor). It may be concluded that MP-4 induces terminal differentiation in leukaemia HL-60 cells in the monocyte pathway. [0024]
  • Serum Interferon Increase Induced by MPs in Mice [0025]
  • Non-inbred white males mice aged 1.5-2 months, body weight 18-20 g, were injected in the peritoneal cavity, with a single dose of MP-3, MP-4, MP-5 or MP-6: 0.01, 0.1, 1 or 10 μg (per mouse). Each of the experimental groups of animals was represented by 25 mice receiving the same dose of a preparation. 4, 24, 48, 72 or 96 h after injection, 5 mice of each experimental group were sacrificed, their serum samples pooled and stored frozen at −60° C. until the interferon activity of the pooled serum measured. The latter measurement was performed by testing serum anti-viral activity in the in vitro cell cultures infected by encephalomyocarditis virus (EMV). [0026]
  • In more detail, cell cultures of L929 fibroblastoid cell line were grown in alpha-MEM culture medium supplemented with 10% FBS. Cultures of 200,000 cells suspended in 0.1 ml of the culture medium were placed into wells of 96-well microplate and incubated in an atmosphere of 5% CO[0027] 2 at 37° C. The L929 cell cultures were infected using 100 TCIC50 dose of the established laboratory strain of EMV. Cytopathological damage in cell morphology was recorded 24 h from infection.
  • Factor 2 serial dilutions of each serum sample were made using alpha-MEM culture medium containing FBS. 0.1 ml of the designated dilution of serum sample was added into each microwell containing L929 cell culture at the point of its infection with EMV. [0028]
  • On observing L929 cell damage caused by EMV within 24 h, the highest dilution of a serum conferring 50% inhibition of the viral infection was recorded. The reverse value of such highest dilution was taken as an interferon titer of the serum represented in Units/ml. [0029]
  • In the control groups of mice, the strongest of known interferon inducers were used. Namely, Newcastle disease virus (NDS) and Ridostin were used as a positive control to be compared with MPs by their serum interferon-increasing activity. [0030]
  • Two phases of visible increase of early (4 h) and late (48 h) interferon were observed in the mouse serum after a single injection of Serum interferon levels of 40 and 80 units/ml were reached, at 0.1 μg MP-4. [0031]
  • A single injection of 0.01 μg MP-5 led to a very strong increase of late (48 h) serum interferon. The serum interferon titers reached 320 units/ml, the level characteristic Ridostin, one of the strongest interferon inducers yet known. [0032]
  • MP-3 and MP-6 weakly induced late interferon in the mouse serum. Levels of 20 and 40 units/ml, respectively, were achieved 48 h after a single injection of 1-10 μg MP-3 and 0.1-1 μg MP-6. [0033]
  • Anti-viral Activity of the MPs in vitro [0034]
  • Being capable of inducing serum interferon increase in vivo, the MPs most probably induce synthesis of interferon in the appropriate cell culture in vitro. If so, this can be monitored according to these compounds' anti-viral action in cell culture in vitro, when infected by actively replicating virus. [0035]
  • In vitro culture of L929 mouse cells acutely infected by encephalomyocarditis virus (EMV) was used as a model to define active concentrations of MP-3, MP-4, MP-5 and MP-6 as related to their capability to induce interferon synthesis in mammalian cells and hence block viral infection in these cells. The L929 mouse fibroblastoid cell line was maintained in vitro as described above. MP-3, MP-4, MP-5 and MP-6 were added into triplicate cultures using the following final concentrations: 500, 250, 125, 63, 31, 16, 8, 4, 2, 1, 0.5, 0.25 μg per 1 ml of culture. Ridostin was used as a control interferon-inducer. [0036]
  • 24 or 48 h post-injection, the L929 cell cultures were infected by 100 TCID[0037] 50 of EMV. During the next 24 h the viral infection caused dramatic damages in L929 cells. When the cultures were pre-incubated in the presence of MP-3, it did not prevent the cell layers from extensive damage caused by subsequent virus infection using 100 TCID50 of EMV. MP-5, by contrast, when added in a final concentration of 16 μg/ml or more, completely abrogated destructive influence of the virus on L929 cells. So did MP-6, when added at a concentration of 4 μg/ml or more. The anti-viral effect of MP-5 and MP-6 was quite comparable to that of Ridostin added at 0.5 μg/ml or more. MP-4 also defended the L929 cells from the virus-induced damage, after 48 h exposure of the cells in the presence of 32 μg/ml (or higher concentration) of the preparation before their challenge by the virus.
  • Interferon Induction by MPs in Human Cells in vitro [0038]
  • The interferon-inducing capacities of the MPs was examined in both L-41 human cell line and healthy donor peripheral blood cell (PBC) cultures. L-41 cells were maintained in medium 199 supplemented by 10% FBS and antibiotics. 200,000 cells per 1 ml of culture medium were placed in the wells of 24-well plastic culture plates and grown at 37° C. in the atmosphere of 5% CO[0039] 2/ When a cell monolayer was formed, the control and experimental interferon-inducers were introduced in the cultures in the centration desired. 24 h after interferon induction, the culture supernatants were harvested and then examined for interferon content.
  • The healthy donor PBC were incubated in the wells of 96-well culture plates and the culture supernatants were harvested 24 h after the test preparation was added to the culture. [0040]
  • To measure the interferon activity of the supernatants harvested, serial dilutions of the supernatants were prepared and then added into fresh L-41 cultures infected using 100 TCID[0041] 50 of EMV. The interferon titer of the supernatant was recorded, as described above for interferon titration of the mouse serum in cultures of mouse L929 cells.
  • 1 μg/ml MP-3 induced an intensive production of interferon by human cells, both L41 and donor PBC. 0.01 μg/ml MP-4 showed induction of interferon synthesis comparable to MP-3 in L-41 cells. MP-5 at small doses (0.001 μg/ml induced interferon in donor PBC, and at larger doses (1 μg/ml) was active with L-41 cells. MP-6 induced relatively small amounts of interferon in both L-41 and donor PBC. [0042]
  • HIV-Inhibition by MPs in vitro [0043]
  • The anti-viral activity of MP-3, MP-4, MP-5 and MP-6 was examined using in vitro culture of MT4 cells, a human T-lymphoblastoid cell line infected by HIV. As a source of infective virus, the laboratory HT HIV 27 virus strain was used. It was capable of causing chronic HIV-infection, with the production of non-damaged HIV-1 infective particles in MT4 cells in vitro. [0044]
  • The intensity of HIV infection and the respective anti-HIV influence of the MPs was evaluated according to the following criteria: [0045]
  • (a) alterations of normal MT4 cell morphology induced by HIV (cytopathogenic effect); [0046]
  • (b) HIV antigens found in infected MT4 cells using luminescence microscopy of the cells pre-labelled with fluorescent anti-HIV antibodies; [0047]
  • (c) HIV proteins detected in HIV-infected MT4 cell culture medium using immunofluorescence. [0048]
  • The HIV-infected MT4 cells were incubated in RPMI-1640 culture medium supplemented with 10% FBS and 2 mM L-glutamine. The MT4 cells (0.5 million cells per 1 ml of culture medium) were placed in wells of a 24-well plastic culture plates and kept for 7 days of 37° C. in an atmosphere of 4.5% CO[0049] 2. Each of the MPs examined was added into respective wells of the culture plates, to final concentrations of 0.1, 0.5, 1, 5, 10, 50 and 100 μg per 1 ml of culture were used. Azidothymidine (Sigma Chemical Co.) at its final concentration of 0.1 μg/ml, was used as a positive anti-viral control during each of the experiments.
  • Standard cell viability tests performed 24 h from cultivation showed MP-3, MP-4, MP-5 and MP-6 caused no visible damage of MT4 cells growing in vitro. Of these four compounds, the most pronounced anti-HIV activity was observed with MP-3. In the presence of 1-5 μg/ml or higher concentration of MP-3, HIV replication was completely stopped: no cytopathogenic effect or production of viral protein was recorded in such cultures. 50% inhibition of HIV replication was observed in the presence of 10 μg/ml MP-4. MP-5 and MP-6 did not influence on HIV replication in MT4 cell cultures in vitro. Azidothymidine (0.1 μg/ml) caused 100% inhibition of HIV replication in the infected MT-4 cells. [0050]
  • 1 6 1 6 PRT Sus species 1 Phe Leu Gly Phe Pro Thr 1 5 2 6 PRT Sus species 2 Leu Val Val Tyr Pro Trp 1 5 3 6 PRT Sus species 3 Leu Val Cys Tyr Pro Gln 1 5 4 8 PRT Sus species 4 Phe Arg Pro Arg Ile Met Thr Pro 1 5 5 5 PRT Sus species 5 Val Val Tyr Pro Asp 1 5 6 4 PRT Sus species 6 Val Asp Pro Pro 1

Claims (15)

We claim:
1. A peptide comprising 4 to 10 amino acids including X1-Pro, Pro-X2 or X1-Pro-X2, wherein X1 and X2 are independently selected from Lys, Arg, His, Asp, Glu, Asn and Gln, and the other amino acids are independently selected from Gly, Ala, Val, Leu, Ile, Nle, Nva, Pro, Phe, Tyr, Trp, Cys, Met, Ser and Thr.
2. The peptide according to claim 1, which comprises predominantly other amino acids as defined in claim 1.
3. The peptide according to claim 1, wherein the N-terminal comprises 1, 2, 3 or 4 amino acids independently selected from Gly, Ala, Val, Leu, Ile, Nle, Nva, Phe, Tyr, Trp, Cys and Met.
4. The peptide according to claim 1, including Pro-X2.
5. The peptide according to claim 1, wherein X2 is a terminal amino acid.
6. The peptide according to claim 1, including X1-Pro.
7. The peptide according to claim 6, including Z-X1-Pro, wherein Z is terminal and one of the other amino acids.
8. The peptide according to claim 1, which is or comprises LVCYPQ (SEQ ID NO. 3).
9. The peptide according to claim 1, which is or comprises FRPRIMTP (SEQ ID NO. 4).
10. The peptide according to claim 1, which is or comprises VVYPD (SEQ ID NO. 5).
11. The peptide according to claim 1, which is or comprises VDPP (SEQ ID NO. 6).
12. The peptide according to claim 1, free from other components of bone marrow.
13. The peptide according to claim 1, in a pharmaceutically acceptable carrier or diluent.
14. The peptide according to claim 2, wherein the N-terminal comprises 1, 2, 3 or 4 amino acids independently selected from Gly, Ala, Val, Leu, Ile, Nle, Nva, Phe, Tyr, Trp, Cys and Met.
15. A method for the treatment or prophylaxis of a viral or bacterial infection, or a disease requiring immunostimulation, in a patient, said method comprising administering an effective amount of a peptide of claim 1 to the patient.
US10/277,622 1997-01-07 2002-10-22 Myelopeptides and their therapeutic use Abandoned US20030083236A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/277,622 US20030083236A1 (en) 1997-01-07 2002-10-22 Myelopeptides and their therapeutic use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9700154.9 1997-01-07
GBGB9700154.9A GB9700154D0 (en) 1997-01-07 1997-01-07 Peptides
US09/341,173 US6469137B1 (en) 1997-01-07 1998-01-07 Myelopeptides and their therapeutic use
US10/277,622 US20030083236A1 (en) 1997-01-07 2002-10-22 Myelopeptides and their therapeutic use

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB1998/000030 Continuation WO1998030581A1 (en) 1997-01-07 1998-01-07 Myelopeptides and their therapeutic use
US09/341,173 Continuation US6469137B1 (en) 1997-01-07 1998-01-07 Myelopeptides and their therapeutic use

Publications (1)

Publication Number Publication Date
US20030083236A1 true US20030083236A1 (en) 2003-05-01

Family

ID=10805577

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/341,173 Expired - Fee Related US6469137B1 (en) 1997-01-07 1998-01-07 Myelopeptides and their therapeutic use
US10/277,622 Abandoned US20030083236A1 (en) 1997-01-07 2002-10-22 Myelopeptides and their therapeutic use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/341,173 Expired - Fee Related US6469137B1 (en) 1997-01-07 1998-01-07 Myelopeptides and their therapeutic use

Country Status (9)

Country Link
US (2) US6469137B1 (en)
EP (1) EP0960122A1 (en)
JP (1) JP2001508435A (en)
AU (1) AU728539B2 (en)
CA (1) CA2274731A1 (en)
GB (1) GB9700154D0 (en)
NZ (1) NZ336243A (en)
RU (1) RU2198178C2 (en)
WO (1) WO1998030581A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070271264A1 (en) * 2006-05-16 2007-11-22 Khemdut Purang Relating objects in different mediums
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
EP3520816A2 (en) 2009-10-23 2019-08-07 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and related compositions and methods

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1403474A (en) * 2001-09-05 2003-03-19 中国人民解放军军事医学科学院生物工程研究所 Short peptide and medicine with short peptide as active component
WO2008020778A1 (en) * 2006-07-31 2008-02-21 Institut Molekulyarnoi Genetiki Rossiiskoi Akademii Nauk (Img Ran) Analgetically active peptide family
RU2585494C2 (en) * 2014-09-17 2016-05-27 Федеральное государственное бюджетное учреждение "Государственный научный центр Институт иммунологии" Федерального медико-биологического агентства России Recombinant protein rec-mp, containing sequence of myelopeptides for treating secondary immunodeficiency conditions
JP2022554151A (en) 2019-10-23 2022-12-28 ノバ ケミカルズ（インターナショナル）ソシエテ アノニム Biaxially oriented MDPE film

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939391A (en) * 1993-03-31 1999-08-17 Pro-Neuron, Inc. Hemoglobin alpha chain peptide fragments useful for inhibiting stem cell proliferation
IL106214A (en) * 1993-07-01 1998-12-06 Yeda Res & Dev Thf-gamma2 analogs and pharmaceutical compositions comprising them
WO1995030007A1 (en) * 1994-05-02 1995-11-09 University Of Washington Thymidine kinase mutants
WO1996018652A1 (en) * 1994-12-16 1996-06-20 Mikhailova Augusta A Hexapeptides possessing antitumor activity
US6074872A (en) * 1996-05-15 2000-06-13 The Scripps Research Institute Cortistatin: nucleic acids that encode these neuropeptides

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070271264A1 (en) * 2006-05-16 2007-11-22 Khemdut Purang Relating objects in different mediums
EP3520816A2 (en) 2009-10-23 2019-08-07 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and related compositions and methods
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
US9662405B2 (en) 2012-04-26 2017-05-30 Thomas Jefferson University Method of treating cancer by administering chimeric antigen receptor comprising anti-GCC antibody

Also Published As

Publication number Publication date
CA2274731A1 (en) 1998-07-16
AU5490998A (en) 1998-08-03
EP0960122A1 (en) 1999-12-01
US6469137B1 (en) 2002-10-22
JP2001508435A (en) 2001-06-26
RU2198178C2 (en) 2003-02-10
AU728539B2 (en) 2001-01-11
GB9700154D0 (en) 1997-02-26
NZ336243A (en) 2001-04-27
WO1998030581A1 (en) 1998-07-16

Similar Documents

Publication Publication Date Title
RU2060998C1 (en) Method of synthesis of peptides, peptides, immunomodulating composition and a method of regulation of insufficient or excessive function of t-cells in patient
Dessaint et al. Inhibition of lymphocyte proliferation by factor (s) produced by Schistosoma mansoni
EA007217B1 (en) Casein derived peptides and uses thereof in therapy
JPH09509175A (en) Broad spectrum antimicrobial compounds and methods of use
CN106232616A (en) Amphipathic synthetic antibacterial peptide, its medical composition and its use
US6469137B1 (en) Myelopeptides and their therapeutic use
CA2180119C (en) The composition containing snapping turtle and tortoise, the preparation and the use thereof
Nishioka et al. Tuftsin: an immunomodulating peptide hormone and its clinical potential as a natural biological response modifier
JPH04279597A (en) New peptide, angiotensinase inhibitory peptide and per oral composition containing the same peptide
US5723504A (en) Amadori reaction compounds and products, process for their manufacture, and their use as cytokine inducers
CN1107335A (en) Enzymolytic pearl liquor
US4482543A (en) Biologically active substance, process for preparing the substance and immunoactive composition
EP0466498B1 (en) Physiologically active peptides having immunoregulatory activities
Lebeurier et al. Carboxy‐terminal peptides (C1–24 and C13–24 but not C1–13) of platelet factor 4 inhibit murine megakaryocytopoiesis, an activity which is neutralized by heparin
Gaál et al. Immunomodulatory Effect of Synthetic Branched Polypeptides. II.
CA2372468C (en) Compounds exhibiting an antibiotic activity
JP2570670B2 (en) Toxoplasma growth inhibitor
BE1000263A4 (en) A tripeptide immunostimulatory activity.
CN113730549B (en) Application of milk-derived active peptide CCL-1S in preparation of sleep-promoting product
KR100262468B1 (en) Peptide that inhibits blood triglyceride level rise and blood triglyceride level rise inhibitor containing said peptide as active ingredient
US20010056061A1 (en) Synthetic, statistic thymic peptide combination and its use as a preparation with immunological and/or endocrinological effect
JP2794094B2 (en) New peptides and antihypertensives
RU2283663C1 (en) Immunomodulator with antitumor activity and drug based on the same
RU2132681C1 (en) Interferon inducing agent
GB2144128A (en) The tripeptide eisenin and carcinostatic compositions having an immunopotentiating carcinostatic effect which contain it

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: ZERONORTH, INC., MASSACHUSETTS

Free format text: CHANGE OF NAME;ASSIGNOR:CYBRIC INC.;REEL/FRAME:051089/0585

Effective date: 20190429